← Back
Life

Briefing: A setback for Roche’s breast cancer drug

Strategic angle: Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news

Editorial Staff1 min

Summary

  • Summary pending editorial review.

Key Facts

  • Key facts pending editorial review.

Sources